While ICIs such as nivolumab, pembrolizumab (anti-PD-1), and atezolizumab (anti-PD-L1) are approved for EGFR wild-type lung cancer treatment, their effectiveness is limited by both intrinsic and acquired resistance. The gene discussed is EGFR; the disease is lung cancer.